Announcements Trials
Browse Landscape

Phase

Phase 1/2 1

Status

Active not recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Sarcoma 1

Conditions

Lymphoma, Follicular 8Sarcoma 3Lymphoma, B-Cell 3Lymphoma 3Prostatic Neoplasms 2Lymphoma, T-Cell, Peripheral 2Lymphoma, Large B-Cell, Diffuse 2Tertiary Lymphoid Structures 1Squamous Cell Carcinoma of Head and Neck 1Solid Tumor 1Rhabdoid Tumor 1Recurrence 1Pancreatic Neoplasms 1Neurofibrosarcoma 1Nerve Sheath Neoplasms 1Lymphoma, T-Cell 1Lymphoma, Non-Hodgkin 1Lymphoma, Mantle-Cell 1Leukemia, Myeloid, Acute 1Leukemia 1Inhibition, Psychological 1Immunoblastic Lymphadenopathy 1Enteropathy-Associated T-Cell Lymphoma 1Colorectal Neoplasms 1Chordoma 1

Interventions

Nivolumab 5palbociclib 2Radiosurgery 2Protons 2Proton Therapy 2Pemetrexed 2Ipilimumab 2Imatinib Mesylate 2tazemetostat 1relatlimab 1pembrolizumab 1nilotinib 1camrelizumab 1apatinib 1Zoledronic Acid 1Thiotepa 1Surveys and Questionnaires 1Radiotherapy, Intensity-Modulated 1Radiotherapy 1Photochemotherapy 1Peripheral Blood Stem Cell Transplantation 1Panobinostat 1Melphalan 1Mastectomy, Segmental 1Immunoglobulin G 1Granulocyte Colony-Stimulating Factor 1Filgrastim 1Disulfides 1Dihematoporphyrin Ether 1Dasatinib 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
OTHER × Chordoma × tazemetostat × Clear all
NCT05407441 2026-04-13

Tazemetostat+Nivo/Ipi in INI1-Neg/SMARCA4-Def Tumors

Dana-Farber Cancer Institute

Phase 1/2 Active not recruiting
49 enrolled
Sarcoma

Chordoma, Sarcoma, Rhabdoid Tumor

Data powered by HemOnc (CC BY 4.0) Colophon âš¡